Submission Details
| 510(k) Number | K954214 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 07, 1995 |
| Decision Date | January 21, 1997 |
| Days to Decision | 502 days |
| Submission Type | Traditional |
| Review Panel | Pathology (PA) |
| Summary | Summary PDF |
K954214 is an FDA 510(k) clearance for the CEP X SPECTRUMORANGE\Y SPECTRUMGREEN DNA PROBE KIT, a Dna-probe Kit, Human Chromosome X And Y, Bmt Engraftment (Class II — Special Controls, product code OXP), submitted by Vysis (Downers Grove, US). The FDA issued a Cleared decision on January 21, 1997, 502 days after receiving the submission on September 7, 1995. This device falls under the Pathology review panel. Regulated under 21 CFR 866.6010.
| 510(k) Number | K954214 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 07, 1995 |
| Decision Date | January 21, 1997 |
| Days to Decision | 502 days |
| Submission Type | Traditional |
| Review Panel | Pathology (PA) |
| Summary | Summary PDF |
| Product Code | OXP — Dna-probe Kit, Human Chromosome X And Y, Bmt Engraftment |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.6010 |
| Definition | X/y Dna Probe Kit Is Intended To Detect Alpha Satellite Sequences In The Centromere Of Chromosome (chr) X And Satellite Iii Dna At Yq12 Of Chr Y Along With Routine Diagnostic Cytogenetic Testing. It Is Indicated For Use As An Adjunct To Standard Cytogenetic Analysis For Identifying And Enumerating Chr X And Y Via Fish In Interphase Nuclei And Metaphase Spreads Obtained From Bone Marrow (bm) Specimens In Recipients Of Opposite-sex Bm Transplantation (bmt) For Hematological Disorders. It Is Not Intended To Be Used As A Stand Alone Assay For Test Reporting; In Subjects With Like-sex Bmt; In Diagnostic Testing Or Screening For Constitutional X And Y Chr Aneuploidies. |